Business · 24/10/2002Updated: 10/17/2026 · 1 min read
FDA Amends MIFEPREX Patent Extension Review Period
Summary
The FDA is updating its regulatory review period for MIFEPREX, following comments received, and publishing the change as required by law, in response to a notice published in the Federal Register on January 25, 2002.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →